Expression Pattern and Clinicopathological Relevance of the Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase Protein in Colorectal Cancer

Disease Markers - Tập 2016 - Trang 1-9 - 2016
I-Chien Chen1, Kuen‐Haur Lee2,3, Ying-Hua Hsu2,4, Weiran Wang5, Chuan‐Mu Chen1, Ya‐Wen Cheng2,3
1Department of Life Sciences, and Agricultural Biotechnology Center, National Chung Hsing University, Taichung 402, Taiwan
2Cancer Center, Taipei Medical University Hospital, Taipei Medical University, Taipei 110, Taiwan
3Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan
4Department of Chemical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan
5Graduate Institute of Medical Sciences, Collage of Medicine, Taipei Medical University, Taipei 110, Taiwan

Tóm tắt

Aims. Cancer cells use the indoleamine 2,3-dioxygenase 1 (IDO1) pathway to suppress the host’s immune response in order to facilitate survival, growth, invasion, and metastasis of malignant cells. Higher IDO1 expression was shown to be involved in colorectal cancer (CRC) progression and to be correlated with impaired clinical outcome. However, the potential correlation between the expression of IDO1 in a CRC population with a low mutation rate of theAPCgene remains unknown.Material and Methods. Tissues and blood samples were collected from 192 CRC patients. The expressions of IDO1, tryptophan 2,3-dioxygenase (TDO2), and beta-catenin proteins were analyzed by immunohistochemistry. Microsatellite instability (MSI) was determined by PCR amplification of microsatellite loci.Results. The results showed that high IDO1 or TDO2 protein expression was associated with characteristics of more aggressive phenotypes of CRC. For the first time, they also revealed a positive correlation between the abnormal expression of beta-catenin and IDO1 or TDO2 proteins in a CRC population with a low mutation rate ofAPC.Conclusion. We concluded that an IDO1-regulated molecular pathway led to abnormal expression of beta-catenin in the nucleus/cytoplasm of CRC patients with low mutation rate ofAPC, making IDO1 an interesting target for immunotherapy in CRC.

Từ khóa


Tài liệu tham khảo

10.3322/caac.21220

10.1053/j.gastro.2010.01.056

10.3390/cancers5020676

2014, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 57, 302, 10.1007/s00103-013-1911-2

10.1146/annurev-pathol-011110-130235

10.1016/s0092-8674(00)81333-1

10.1186/1476-4598-10-101

10.1126/science.275.5307.1787

10.1111/codi.12318

10.1111/j.1365-2362.2011.02641.x

10.1007/s00384-007-0373-0

10.1016/j.cell.2011.02.013

10.1038/onc.2008.35

10.1097/mog.0b013e32835c9cb3

10.1046/j.1440-1711.2003.t01-1-01177.x

10.1053/j.gastro.2013.05.002

10.1038/bjc.2011.513

10.1002/rcm.4013

1998, Cancer Research, 58, 5248

10.3389/fimmu.2014.00673

10.1111/cas.12705

10.1158/2159-8290.CD-12-0014

2013, International Journal of Clinical and Experimental Pathology, 6, 431

2001, Clinical Cancer Research, 7, 4013

10.1136/gut.2005.070946

10.1038/nrclinonc.2009.237

10.5114/pjp.2015.54953

10.1007/s00384-011-1408-0

10.1158/1055-9965.epi-09-1154

10.1158/1078-0432.ccr-15-0420

10.1517/14728222.2014.995092

10.1309/4e4w-g3ay-gjnc-d11p

10.1016/j.cell.2009.02.037

10.2217/IMT.09.21

10.1007/s11033-014-3080-2

10.1016/0092-8674(90)90186-I

10.3390/ijms140816365

10.1007/s13277-014-1845-9

10.1097/mib.0000000000000278

10.3748/wjg.v7.i3.352

10.1136/gut.2005.066514

10.1093/carcin/bgh117

10.1038/359235a0

10.3748/wjg.v10.i24.3688

1999, Journal of Clinical Oncology, 17, 1364, 10.1200/JCO.1999.17.5.1364

10.1002/jcp.20310

10.1002/ijc.10405

10.1080/152873901300018057

2001, Journal of Clinical Oncology, 19, 299, 10.1200/JCO.2001.19.2.299

10.1093/carcin/bgh177

10.1016/S0002-9440(10)64102-8

10.1038/sj/onc/1205466

10.1093/carcin/bgh074

10.1093/jnci/djq031

10.1136/gut.2010.217182

10.1038/nrclinonc.2011.122

10.1097/ede.0000000000000471

Thông tin
Thông tin xuất bản

Disease Markers

Tập 2016

1-9

Thông tin tác giả